Hardman & Co Research: Avacta: Commendable rate of progress

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Avacta (AVCT): Commendable rate of progress 
 
17-Apr-2018 / 07:15 GMT/BST 
 
*Hardman & Co Research: Commendable rate of progress* 
 
Avacta is a pre-clinical biotechnology company and the proprietary owner of 
Affimer technology. Affimers represent a radical alternative to the 
established antibody technology, which continues to dominate the drug 
industry, despite its limitations. The significant technical and commercial 
benefits of Affimers is being recognised though increased corporate interest, 
on-going evaluations, and deal flow. Meanwhile, AVCT has made stunning 
progress in its strategic goal to enter first-in-man trials in 2020, which now 
looks likely to be with a valuable bi-specific Affimer immuno-oncology asset. 
 
Please click here for the full report: 
 
http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/17.0 
4.18-commendable-rate-of-progress.pdf [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the UK and abroad with outstanding research, investor engagement 
programmes and advisory services. Some of our notes have been commissioned by 
the company which is the subject of the note; this is clearly stated in the 
disclaimer where this is the case. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
675067 17-Apr-2018 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=235e4ca3e597c2dd1ee036f8a9fa0d2e&application_id=675067&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 17, 2018 02:14 ET (06:14 GMT)